✨ Free AI Report
Definium Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Definium Therapeutics, Inc.
Research Preview

Definium Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Definium Therapeutics is a late-stage clinical biopharmaceutical company developing therapeutics intended to address underlying causes of psychiatric and neurological disorders. The company rebranded in January 2026 f...

Analyst-debate audio for Definium Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Definium Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Definium Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
8/ 10Strong

Cyborg Score thesis

Late-stage psychiatric therapeutic candidate with Phase 3 validation, FDA breakthrough status, and runway to accelerate DT120...

Read the full analyst-debate transcript →
Industry Neurology Drugs
3 named competitors
2 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest Definium Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Definium Therapeutics, Inc. Overview

Pro stress-test →

Definium Therapeutics is a late-stage clinical biopharmaceutical company developing therapeutics intended to address underlying causes of psychiatric and neurological disorders. The company rebranded in January 2026 from its former identity MindMed, reflecting its focus on a late-stage psychiatry pipeline anchored by DT120 ODT, a lysergide tartrate compound with FDA Breakthrough Therapy Designation for generalized anxiety disorder.

Strategic Profile

Pro stress-test →

Definium is preparing for landmark FDA submissions in 2027 after completing three successful Phase 3 trials in anxiety and depression. As of 2025 full-year results, the company reported $411.6 million in cash, cash equivalents, and investments sufficient to fund operations into 2028.

Competitive Landscape

Pro stress-test →

Definium competes in the emerging psychedelic medicine space against specialized psychiatric biotech companies. Primary competitors include Compass Pathways (NASDAQ: CMPS), developing psilocybin therapies for treatment-resistant depression; Atai Life Sciences/AtaiBeckley (NASDAQ: ATAI), with a diversified psychiatric pipeline; and GH Research (NASDAQ: GHRS), focused on ketamine-derived therapies. Definium's differentiation rests on Phase 3 validation for DT120 in anxiety and depression, FDA Breakthrough Therapy designation, and capital strength to execute late-stage development.

Industry Context

Definium Therapeutics, Inc. operates in Neurology Drugs.

Key facts

Founded: 2010 · Headquarters: New York, United States · Employees: 105 · Revenue: Private biopharmaceutical company—no product revenue; pre-commercial stage. Operating expenses dominate financials. · Market cap: $5.03 billion (as of October 9, 2026)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Definium Therapeutics, Inc..

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Definium Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Compass PathwaysPsilocybin-assisted therapy for treatment-resistant depression→Atai Life SciencesDiversified psychiatric and neurological therapeutic platform→GH ResearchKetamine-based treatments for psychiatric disorders→

Compare Definium Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Definium Therapeutics, Inc. operates in Neurology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Neurology Drugs research →
NEW · MCP server

Ask your AI assistant about Definium Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Definium Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Definium Therapeutics, Inc. do this quarter?”
“Is Definium Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Definium Therapeutics, Inc. do?+
Definium Therapeutics is a late-stage clinical biopharmaceutical company developing therapeutics intended to address underlying causes of psychiatric and neurological disorders. The company rebranded in January 2026 f...
What is Definium Therapeutics, Inc.'s Cyborg Score?+
Definium Therapeutics, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Definium Therapeutics, Inc.'s main competitors?+
Named competitors include Compass Pathways, Atai Life Sciences, GH Research. The full competitive landscape is in the AskCyborg report.
How can I get the full Definium Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Definium Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Definium Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.